MCKESSON CORPORATION v. ANGEL BOLTON
Opinion
SECOND DIVISION
RICKMAN, P. J.,
GOBEIL and DAVIS, JJ.
NOTICE: Motions for reconsideration must be physically received in our clerk’s office within ten days of the date of decision to be deemed timely filed.
https://www.gaappeals.us/rules
February 12, 2026
In the Court of Appeals of Georgia A25A2089. MCKESSON CORPORATION v. BOLTON et al.
DAVIS, Judge.
In this action under the Drug Dealer Liability Act (“DDLA”), OCGA § 51-1-46, McKesson Corporation seeks interlocutory review of the trial court’s order denying its motion to dismiss. McKesson argues that (1) the trial court erred in finding that the general 20-year statute of limitation prescribed by OCGA § 9-3-22 applies to the claims in this case instead of the 2-year statute of limitation for personal injuries under OCGA § 9-3-33; and (2) it is immune from the DDLA as a licensed practitioner acting in the course of its professional practice. We agree with McKesson that the plaintiffs’ claims in this case under the DDLA are subject to the 2-year statute of
limitation, and we accordingly reverse the trial court’s denial of McKesson’s motion to dismiss.
On appeal of a trial court’s ruling on a motion to dismiss, our review is de novo. However, we construe the pleadings in the light most favorable to the plaintiff with any doubts resolved in the plaintiff’s favor. Our role is to determine whether the allegations of the complaint, when construed in the light most favorable to the plaintiff, and with all doubts resolved in the plaintiff’s favor, disclose with certainty that the plaintiff would not be entitled to relief under any state of provable facts.
Karekezi v. Pinnacle Systems, 367 Ga. App. 391, 391 (885 SE2d 235) (2023) (quotation marks omitted).
According to the allegations of the operative complaint, Angel and Christopher Bolton are the adult children of Kevin Bolton, who obtained prescriptions for opioids and other controlled substances without a legitimate medical purpose. Kevin became dependent upon controlled substances, and Angel and Christopher contend that this addiction caused them physical, mental, emotional, and economic harm. Kevin eventually overdosed and died on February 21, 2016.
Kevin obtained his prescriptions for opioids from Dr. Frank Bynes and filled his prescriptions at Pembroke Pharmacy. McKesson is a pharmaceutical distributor that
distributed opioids to Pembroke Pharmacy. The dosages listed in the prescriptions were over five times the daily dosage recommended by the Centers for Disease Control to prevent overdose. In 2019, Dr. Bynes was convicted in federal court of health care fraud and illegal dispensation of controlled substances, and Kevin’s father testified at Dr. Bynes’ sentencing hearing. McKesson had a long-term relationship with Pembroke Pharmacy, and the Boltons allege that Pembroke Pharmacy was making excessive purchases of controlled substances and that McKesson did not report these purchases to the Georgia Drug and Narcotics Agency pursuant to OCGA § 26-4-115.
Angel and Christopher filed their initial complaint on February 20, 2018, against Dr. Bynes, Pembroke Pharmacy, and multiple other entities, but they did not name McKesson as a defendant.1 On April 5, 2018, Angel and Christopher filed an amended complaint, naming McKesson as a defendant for the first time, and they eventually filed a fourth amended complaint raising a single claim under the DDLA. McKesson moved to dismiss the claim against it, arguing among other things that (1)
1 The initial complaint listed a fictitious “John Doe Corporation” as a defendant, but the Boltons alleged that this fictitious corporation was Dr. Bynes’ employer.
the complaint was time barred, as the applicable two-year statute of limitation for personal injury had run; and (2) the DDLA did not apply to it as a licensed distributor of controlled substances.
The trial court granted the motion to dismiss in part and denied the motion to dismiss in substantial part. The trial court first concluded that it was incapable of determining whether McKesson is immune as a licensed distributor at the motion to dismiss stage. As for the statute of limitation, the trial court first concluded that Angel and Christopher’s amended complaint did not relate back under OCGA § 9-11-15 (c) to the time the original complaint was filed, and it rejected Angel and Christopher’s arguments as to tolling, so as a result it granted McKesson’s motion to dismiss certain personal injury damages relating to the wrongful death of Kevin and his medical expenses that were not paid by Angel and Christopher. However, the trial court concluded that Angel and Christopher could seek recovery of the amount they spent on Kevin’s healthcare and could seek non-economic damages under the DDLA that would be unavailable otherwise in a traditional tort action because the 20-year statute of limitation in OCGA § 9-3-22 applied to any part of their DDLA claim that was not
cognizable under standard tort law. We granted McKesson’s application for interlocutory review.
1. McKesson first argues that this action is time-barred as the facts of this case occurred more than two years before the Plaintiffs filed suit. McKesson argues that the Boltons sought remedies for personal injury and the statute of limitation for such actions is two years and that the trial court erred by applying the 20-year statute of limitation of OCGA § 9-3-22. We agree.
Passed in 1997, the DDLA was intended to “provide a civil remedy for damages to persons in a community injured as a result of illegal drug use.” OCGA § 51-1-46(b). The DDLA was designed to “shift, to the extent possible, the cost of the damage caused by the existence of an illegal drug market in a community to those who illegally profit from that market.” Id. Under the Act, “[a] person injured by an individual drug abuser may bring an action under this Code section for damages against a person who participated in illegal marketing of the controlled substance used by the individual abuser.” OCGA § 51-1-46(d)(1). The Act defines participating in illegal drug marketing as “[m]anufacturing, distributing, or delivering or attempting or conspiring to manufacture, distribute, or deliver, a controlled substance” in violation of state or
federal law. OCGA § 51-1-46(c)(9)(A). The DDLA does not contain its own statute of limitation. See OCGA § 51-1-46.
OCGA § 9-3-33 provides that “actions for injuries to the person shall be brought within two years after the right of action accrues[.]” This provision is a “traditional general statute of limitations[,]” and “the scope of the application of this statute of limitation is determined by the nature of the injury sustained, rather than the legal theory underlying the claim for relief.” Daniel v. American Optical Corp., 251 Ga. 166, 168(1) (304 SE2d 383) (1983). Thus,
Georgia follows a specialized rule for determining the limitation period applicable to personal injury claims: ... an action to recover for personal injuries is, in essence, a personal injury action, and, regardless of whether it is based upon an alleged breach of an implied warranty or is based upon an alleged tort, the limitations statute governing actions for personal injury is controlling.
Gropper v. STO Corp., 250 Ga. App. 820, 822(1) (552 SE2d 118) (2001).
On the other hand, OCGA § 9-3-22 provides that “[a]ll actions for the enforcement of rights accruing to individuals under statutes or acts of incorporation or by operation of law shall be brought within 20 years[.]” We have been clear, however, that this statute “does not apply to all cases in which a statutory duty is
violated” and instead applies only in “special cases not provided for by the general statute of limitations.” See Teachers Ret. Sys. of Ga. v. Plymel, 296 Ga. App. 839, 842, 844(1) (676 SE2d 234) (2009) (quotation marks omitted).
Free access — add to your briefcase to read the full text and ask questions with AI
MCKESSON CORPORATION v. ANGEL BOLTON (MCKESSON CORPORATION v. ANGEL BOLTON) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.